



# WHAT TO EXPECT WITH EPKINLY

## A guide to starting treatment

### What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more treatments for their cancer.

EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

### SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS).** CRS is common during treatment with EPKINLY and can be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop symptoms of CRS, including fever of 100.4°F (38°C) or higher, dizziness or lightheadedness, trouble breathing, chills, fast heartbeat, feeling anxious, headache, confusion, shaking (tremors), or problems with balance and movement, such as trouble walking.
- **Neurologic problems.** EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any symptoms of neurologic problems, including trouble speaking or writing, confusion and disorientation, drowsiness, tiredness or lack of energy, muscle weakness, shaking (tremors), seizures, or memory loss.
- **Infections, and Low blood cell counts.**

**Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).**

# We're here to help

Starting a new treatment for your cancer can mean having a lot of questions. This guide is designed to help you and your care partner know **what to expect before, during, and after EPKINLY treatment**. Also included are resources and tools to help you through your treatment.

## What's inside this guide?

- Before treatment ..... 5
- Important Safety Information ..... 6
- What to expect during treatment ..... 11
- What to do after treatment ..... 15
- Treatment Tracker ..... 21
- Appointment Calendar ..... 31



**Care partner tip:** Read this guide with your loved one so that you can plan ahead together and get the most out of their treatment with EPKINLY.

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).



# Plan your treatment

## What should I ask?

Before your appointment for your treatment with EPKINLY, ask your healthcare provider questions to help you plan and prepare.

What do I need to prepare for my visit?

---

---

Where should I go for my treatment?

---

---

Will I need my care partner to drive me to and from my injection visits?

---

---

How long will my visit last? Will I be able to go home right after my treatment?

---

---

Will my insurance cover my treatment?

---

---



Use the Notes pages to write down any other questions you or your care partner may have for your healthcare team.

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).

# EPKINLY is the first-and-only bispecific antibody given as a subcutaneous injection in DLBCL



EPKINLY is a type of immunotherapy called a bispecific antibody.



EPKINLY is a subcutaneous injection, which is given under the skin.



## EPKINLY dosing schedule

**ONCE  
A  
WEEK**

**FOR 12 WEEKS**

then

**ONCE  
EVERY  
2 WEEKS**

**FOR 24 WEEKS**

then

**ONCE  
EVERY  
4 WEEKS**

**AFTER THAT**

Your EPKINLY treatment schedule is divided into cycles that are usually 28 days (4 weeks) long.

Visit [EPKINLY.com](https://www.epkinly.com) for more information about EPKINLY.

### SELECT IMPORTANT SAFETY INFORMATION

**Important Warnings—EPKINLY can cause serious side effects, including:**

- **Cytokine release syndrome (CRS).** CRS is common during treatment with EPKINLY and can be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop symptoms of CRS, including fever of 100.4°F (38°C) or higher, dizziness or lightheadedness, trouble breathing, chills, fast heartbeat, feeling anxious, headache, confusion, shaking (tremors), or problems with balance and movement, such as trouble walking.

**Due to the risk of CRS, you will receive EPKINLY on a “step-up” dosing schedule.** The step-up dosing schedule is when you receive smaller “step-up” doses of EPKINLY on day 1 and day 8 of your first cycle of treatment (cycle 1). You will receive your first full dose of EPKINLY on day 15 of cycle 1. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Before each dose in cycle 1, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles.

Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).

**epkinly**<sup>™</sup>  
epcoritamab-bysp  
SUBCUTANEOUS INJECTION 4mg/48mg

# Plan your treatment

## Preparing for your appointment

Here is an overview of some helpful things to know before your visit. Your healthcare provider may also have additional instructions.



### Hydration

It is important that you are adequately hydrated before you receive your EPKINLY injection.

Start drinking plenty of water the day before your visit. Consider bringing water with you on the way to your visit.



### Injection site

Your EPKINLY injection will likely be in the lower abdomen or the thigh.

- Wear loose clothing that is easy to change out of
- Prepare a cold pack in your freezer in case of any injection site reaction after treatment



### Planning for your first full dose

Due to the risk of CRS and neurologic problems, you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY in week 3.

- Make sure you discuss with your healthcare provider where you will need to receive this dose so you can plan ahead if this is not near where you live



Your healthcare provider may receive EPKINLY from a specialty pharmacy, depending on your health insurance. Ask your healthcare provider about how he or she will receive your treatment. You may get a call from the pharmacy via a 1-800 number to collect any co-pay or co-insurance.

## SELECT IMPORTANT SAFETY INFORMATION

### Important Warnings—EPKINLY can cause serious side effects, including:

- **Neurologic problems.** EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any symptoms of neurologic problems, including trouble speaking or writing, confusion and disorientation, drowsiness, tiredness or lack of energy, muscle weakness, shaking (tremors), seizures, or memory loss.

Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).

**epkinly**<sup>™</sup>  
epcoritamab-bysp  
SUBCUTANEOUS INJECTION 4mg/148mg

# Important Safety Information

## Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS).** CRS is common during treatment with EPKINLY and can be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop symptoms of CRS, including fever of 100.4°F (38°C) or higher, dizziness or lightheadedness, trouble breathing, chills, fast heartbeat, feeling anxious, headache, confusion, shaking (tremors), or problems with balance and movement, such as trouble walking.

### Due to the risk of CRS, you will receive EPKINLY on a “step-up” dosing schedule.

The step-up dosing schedule is when you receive smaller “step-up” doses of EPKINLY on day 1 and day 8 of your first cycle of treatment (cycle 1). You will receive your first full dose of EPKINLY on day 15 of cycle 1. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Before each dose in cycle 1, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles.

- **Neurologic problems.** EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in

neurologic problems. Tell your healthcare provider right away if you develop any symptoms of neurologic problems, including trouble speaking or writing, confusion and disorientation, drowsiness, tiredness or lack of energy, muscle weakness, shaking (tremors), seizures, or memory loss.

**Due to the risk of CRS and neurologic problems,** you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY on day 15 of cycle 1. Your healthcare provider will monitor you for symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects, and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe.

**Do not** drive or use heavy or potentially dangerous machinery if you develop dizziness, confusion, tremors, drowsiness, or any other symptoms that impair consciousness until your symptoms go away. These may be symptoms of CRS or neurologic problems.

## EPKINLY can also cause other serious side effects, including:

- **Infections.** EPKINLY can cause serious infections that may lead to death. Your healthcare provider will check you for symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any symptoms of

Please see additional Important Safety Information on page 7.  
Please see accompanying [Medication Guide](#).

epkinly™  
epcoritamab-bysp  
SUBCUTANEOUS INJECTION 4mg/48mg



# Important Safety Information (continued)

infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.

- **Low blood cell counts.** Low blood cell counts are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including **low white blood cell counts (neutropenia)**, which can increase your risk for infection; **low red blood cell counts (anemia)**, which can cause tiredness and shortness of breath; and **low platelet counts (thrombocytopenia)**, which can cause bruising or bleeding problems.

Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

**Before you receive EPKINLY, tell your healthcare provider about all of your medical conditions, including if you:**

- have an infection.
- are pregnant or plan to become pregnant. EPKINLY may harm your unborn baby. **Females who are able to become pregnant:** Your healthcare provider should do a pregnancy test before you start treatment with EPKINLY. You should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY.

- are breastfeeding or plan to breastfeed. It is not known if EPKINLY passes into your breast milk. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

**Tell your healthcare provider about all of the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

**The most common side effects of EPKINLY** include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea.

These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

**Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on page 6. Please see [Medication Guide](#).**

# MyNavCare™ is here to support you

With *MyNavCare*, you can receive personalized support throughout your treatment journey from a dedicated team that cares.



## A partner on your treatment journey

Your healthcare provider is your main source for treatment information. With *MyNavCare*, you gain access to additional resources and medication information.

- Dedicated support throughout your treatment
- Information about treatment access and financial support\*
- Insight into independent organizations that may provide additional assistance
- Additional tools and resources that may help along the way



## Financial assistance for eligible patients

*MyNavCare* may be able to help uninsured or underinsured patients receive financial assistance and information. This includes:

- Co-pay assistance program for commercially insured patients\*
- Independent patient assistant foundation information†
- Genmab Patient Assistance Program



## Ongoing personalized support

Your **Patient Engagement Liaison** is an experienced nurse and trained in treatment support as it relates to your specific care.‡ They're dedicated to you, helping to:

- Provide educational information
- Connect you to external organizations
- Offer resources for you and your care partners

Contact a **MyNavCare Support Specialist**  
by calling **1-866-NAV-CARI (1-866-628-2271)**,  
Monday-Friday, 8 AM-8 PM ET.  
Or visit **[MyNavCare.com](https://www.mynavcare.com)** to learn more.

\*Based on eligibility requirements and Terms and Conditions.

†Eligibility criteria is determined by each independent third-party foundation. *MyNavCare* does not determine eligibility and cannot guarantee foundations will offer assistance.

‡Patient Engagement Liaisons are provided by *MyNavCare* Patient Support and do not work under the direction of your doctor or provide medical advice. Patients should speak with their doctor about any treatment-related questions.



# Additional resources

## Support organizations

Here are some organizations that can provide information and support throughout your treatment as well as connect you with others who are going through similar experiences:



### CancerCare

[www.cancercare.org](http://www.cancercare.org) | 800-813-HOPE (4673)



### American Cancer Society

[www.cancer.org](http://www.cancer.org) | 800-227-2345



### Lymphoma Research Foundation

[www.lymphoma.org](http://www.lymphoma.org) | 800-500-9976



### The Leukemia & Lymphoma Society

[www.lls.org](http://www.lls.org) | 800-955-4572



### Family Reach

[www.familyreach.org](http://www.familyreach.org) | 973-394-1411 ext. 1



### Patient Advocate Foundation

[www.patientadvocate.org](http://www.patientadvocate.org) | 800-532-5274

There are many available resources that may be helpful to patients, families, and care partners dealing with cancer. The above resources are not controlled, owned, or endorsed by Genmab/AbbVie, and Genmab/AbbVie is not responsible for their content.

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).



# Important contact information

Write down contact information for members of your healthcare team and other emergency contacts for quick and easy access.

## My Doctor

Name: \_\_\_\_\_

Phone number: \_\_\_\_\_

Office address: \_\_\_\_\_

## My Nurse

Name: \_\_\_\_\_

Phone number: \_\_\_\_\_

Office address: \_\_\_\_\_

## My Pharmacy

Name: \_\_\_\_\_

Phone number: \_\_\_\_\_

Office address: \_\_\_\_\_

## My Emergency Contact

Name: \_\_\_\_\_

Phone number: \_\_\_\_\_

Office address: \_\_\_\_\_

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).



# What to expect during treatment

## How often you will receive EPKINLY

The following outlines a general schedule for when you will receive your treatment. Work with your healthcare provider to determine your appointment dates.

Your EPKINLY treatment schedule is divided into cycles that are usually 28 days (4 weeks) long.

**ONCE  
A  
WEEK**

**FOR 12 WEEKS**

You'll receive an injection once a week for the first 12 weeks

**ONCE  
EVERY  
2 WEEKS**

**FOR 24 WEEKS**

Then, you'll receive an injection every other week for 24 weeks

**ONCE  
EVERY  
4 WEEKS**

**AFTER THAT**

Afterward, it will be a monthly injection

**In the beginning, you will receive EPKINLY based on a “step-up dosing schedule.”**

- During the first 2 weeks of treatment, you will receive smaller "step-up" doses than what you receive in week 3 (first full dose) and for the rest of your treatment. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule
- This is designed to help reduce the risk of a side effect called cytokine release syndrome (CRS)

You will continue to receive EPKINLY for as long as your doctor finds it is working for you and your side effects are manageable.

### SELECT IMPORTANT SAFETY INFORMATION

**Due to the risk of CRS and neurologic problems**, you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY in week 3 (day 15 of cycle 1). Your healthcare provider will monitor you for symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects, and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe.

Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).

**epkinly**<sup>™</sup>  
epcoritamab-bysp  
SUBCUTANEOUS INJECTION 4mg/48mg


# About your injection

Before your healthcare provider administers your injection, he or she will:

- Check your vital signs and ask you some questions about your general health status
- Check to make sure you are adequately hydrated
- Before each dose in the first 4 weeks, you will receive medicines 30-120 minutes before your injection to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future doses

## During your injection

- EPKINLY will be given as an injection under your skin (subcutaneous injection), usually in the lower part of your stomach area (abdomen) or thigh
- Your healthcare provider will likely switch the injection site at each visit (left to right side or vice versa), especially during your first few weeks of treatment
- You may be asked by your healthcare team to stay longer after the injection so that they can monitor for any reactions



Keep track of your injection site locations by using the Treatment Tracker on page 21.



### Care partner tip:

- A cold pack can help with any injection site reactions related to treatment. Remember to prepare the cold pack in the freezer ahead of time
- Make sure your transportation arrangements can accommodate staying longer after the injection if the healthcare team requests it

## SELECT IMPORTANT SAFETY INFORMATION

**Do not** drive or use heavy or potentially dangerous machinery if you develop dizziness, confusion, tremors, drowsiness, or any other symptoms that impair consciousness until your symptoms go away. These may be symptoms of CRS or neurologic problems.

Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).

**epkinly**<sup>™</sup>  
epcoritamab-bysp  
SUBCUTANEOUS INJECTION 4mg/148mg







# What to do after treatment

After you receive EPKINLY, your healthcare provider will monitor you for any side effects from the treatment, and you should also look out for side effects and any changes in how you're feeling afterward.

EPKINLY can cause serious side effects, including cytokine release syndrome (called CRS), which is common during EPKINLY treatment and can be serious or life-threatening, and neurologic problems that can be life-threatening and lead to death. Other serious side effects include infections, and low blood cell counts.

## Watch for symptoms of CRS

### CRS symptoms may include

- Fever 100.4°F (38°C) or higher
- Dizziness or light-headedness
- Trouble breathing
- Chills
- Fast heartbeat
- Feeling anxious
- Headache
- Confusion
- Shaking (tremors)
- Problems with balance and movement, such as trouble walking

**Tell your healthcare provider or get medical help right away if you develop symptoms of CRS.** He or she may give you medicines to treat your side effects. Your healthcare provider may temporarily or completely stop your treatment with EPKINLY, depending on your symptoms.



**Care partner tip:** Monitor your loved one for signs of fever. Use a thermometer to check frequently for fever of 100.4°F or higher in the days following an injection of EPKINLY. Alert the healthcare team if your loved one has a fever of 100.4 or higher following treatment.

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).

**epkinly**<sup>™</sup>  
epcoritamab-bysp  
SUBCUTANEOUS INJECTION 4mg/48mg

## Watch for symptoms of neurologic problems

Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems.

### Symptoms may include but are not limited to

- Trouble speaking
- Confusion and disorientation
- Drowsiness
- Tiredness or lack of energy
- Muscle weakness
- Shaking (tremors)
- Seizures
- Memory loss

**Tell your healthcare provider right away if you develop any symptoms of neurologic problems.** You may be given medicines to treat your side effects, and your treatment with EPKINLY may be temporarily or completely stopped.



**Care partner tip:** Neurologic problems can affect your loved one’s ability to think, remember, and/or use language. These may be subtle or hard to notice at first. If you notice any changes in behavior in your loved one, let the healthcare team know immediately.

## Important things to know

Due to the risk of CRS and neurologic problems, you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY in week 3.

**Do not** drive or use heavy or potentially dangerous machinery if you develop dizziness, confusion, tremors, drowsiness, or any other symptoms that impair consciousness until your symptoms go away. These may be symptoms of CRS or neurologic problems.

## Following up with your healthcare team

**After your first treatment visit for EPKINLY, consider discussing the following with your healthcare team:**

What should I do if I miss a dose? \_\_\_\_\_

\_\_\_\_\_

Is there anything I need to be aware of while I am receiving EPKINLY? \_\_\_\_\_

\_\_\_\_\_

Is there anything I can do to make my overall health better during treatment? \_\_\_\_\_

\_\_\_\_\_

**Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see Medication Guide.**



## Patient Wallet Card

It's always a good idea to be prepared; that's why we created this Patient Wallet Card. You or your care partner can carry it at all times, so if something happens, healthcare providers will have your important information quickly at hand.

**This information is not designed to replace the advice of your healthcare provider. Please reach out to your healthcare team with any questions or concerns you may have.**

### What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more treatments for their cancer. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

### IMPORTANT SAFETY INFORMATION

**Important Warnings—EPKINLY can cause serious side effects, including:**

- **Cytokine release syndrome (CRS).** CRS is common during treatment with EPKINLY and can be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop symptoms of CRS, including fever of 100.4°F (38°C) or higher, dizziness or lightheadedness, trouble breathing, chills, fast heartbeat, feeling anxious, headache, confusion, shaking (tremors), or problems with balance and movement, such as trouble walking.

**Due to the risk of CRS, you will receive EPKINLY on a “step-up” dosing schedule.** The step-up dosing schedule is when you receive smaller “step-up” doses of EPKINLY on day 1 and day 8 of your first cycle of treatment (cycle 1). You will receive your first full dose of EPKINLY on day 15 of cycle 1. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Before each dose in cycle 1, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles.

- **Neurologic problems.** EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any symptoms of neurologic problems, including trouble speaking or writing, confusion and disorientation, drowsiness, tiredness or lack of energy, muscle weakness, shaking (tremors), seizures, or memory loss.

**Please see additional Important Safety Information on the next page. Please see Medication Guide.**



Please remove this card and fold along the dotted lines.

## Patient Wallet Card



Patient name: \_\_\_\_\_ EPKINLY start date: \_\_\_\_\_

Name of prescribing oncologist: \_\_\_\_\_ Office phone: \_\_\_\_\_

**Carry this card with you at all times. Show this card to any healthcare provider involved in your care.**

**Call or see your oncologist or get emergency help right away if you have any of these symptoms:**

#### Cytokine release syndrome (CRS)

- Fever of 100.4°F (38°C) or higher
- Dizziness or light-headedness
- Trouble breathing
- Chills
- Fast heartbeat
- Feeling anxious
- Headache
- Confusion
- Shaking (tremors)
- Problems with balance and movement, such as trouble walking

#### Immune effector cell–associated neurotoxicity syndrome (ICANS)

- Trouble speaking or writing
- Confusion and disorientation
- Drowsiness
- Tiredness or lack of energy
- Muscle weakness
- Shaking (tremors)
- Seizures
- Memory loss

**Please see additional Important Safety Information before separating card or visit EPKINLY.com.**

### IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

This patient is receiving EPKINLY—which may cause serious side effects, including **cytokine release syndrome (CRS)** and **immune effector cell–associated neurotoxicity syndrome (ICANS)**.

- If CRS or ICANS is suspected, please refer to sections 2.6, 5.1, and 5.2 of the EPKINLY full Prescribing Information
- Please follow up with the prescribing oncologist about the management of this event

**For more information about EPKINLY, see full Prescribing Information at EPKINLYhcp.com.**

### IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS (CONT'D)

To learn about adverse reaction management for EPKINLY, scan this QR code or visit EPKINLYhcp.com.



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536. Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064. EPKINLY is a trademark of Genmab A/S ©2023 Genmab A/S and AbbVie. All rights reserved. 05/2023 COM-US-EPK-000187

## IMPORTANT SAFETY INFORMATION (CONT'D)

**Due to the risk of CRS and neurologic problems,** you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY on day 15 of cycle 1. Your healthcare provider will monitor you for symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects, and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe.

**Do not** drive or use heavy or potentially dangerous machinery if you develop dizziness, confusion, tremors, drowsiness, or any other symptoms that impair consciousness until your symptoms go away. These may be symptoms of CRS or neurologic problems.

**EPKINLY can also cause other serious side effects, including:**

- **Infections.** EPKINLY can cause serious infections that may lead to death. Your healthcare provider will check you for symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts.** Low blood cell counts are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including **low white blood cell counts (neutropenia)**, which can increase your risk for infection; **low red blood cell counts (anemia)**, which can cause tiredness and shortness of breath; and **low platelet counts (thrombocytopenia)**, which can cause bruising or bleeding problems.

Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

**Before you receive EPKINLY, tell your healthcare provider about all of your medical conditions, including if you:**

- have an infection.
- are pregnant or plan to become pregnant. EPKINLY may harm your unborn baby. **Females who are able to become pregnant:** Your healthcare provider should do a pregnancy test before you start treatment with EPKINLY. You should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY.
- are breastfeeding or plan to breastfeed. It is not known if EPKINLY passes into your breast milk. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

**Tell your healthcare provider about all of the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements.

**The most common side effects of EPKINLY** include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea.

These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

**Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on previous page. Please see Medication Guide.**



## Patient Wallet Card

It's always a good idea to be prepared; that's why we created this Patient Wallet Card. You or your care partner can carry it at all times, so if something happens, healthcare providers will have your important information quickly at hand.

**This information is not designed to replace the advice of your healthcare provider. Please reach out to your healthcare team with any questions or concerns you may have.**

### What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more treatments for their cancer. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

### IMPORTANT SAFETY INFORMATION

**Important Warnings—EPKINLY can cause serious side effects, including:**

- **Cytokine release syndrome (CRS).** CRS is common during treatment with EPKINLY and can be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop symptoms of CRS, including fever of 100.4°F (38°C) or higher, dizziness or lightheadedness, trouble breathing, chills, fast heartbeat, feeling anxious, headache, confusion, shaking (tremors), or problems with balance and movement, such as trouble walking.

**Due to the risk of CRS, you will receive EPKINLY on a “step-up” dosing schedule.** The step-up dosing schedule is when you receive smaller “step-up” doses of EPKINLY on day 1 and day 8 of your first cycle of treatment (cycle 1). You will receive your first full dose of EPKINLY on day 15 of cycle 1. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Before each dose in cycle 1, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles.

- **Neurologic problems.** EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any symptoms of neurologic problems, including trouble speaking or writing, confusion and disorientation, drowsiness, tiredness or lack of energy, muscle weakness, shaking (tremors), seizures, or memory loss.

**Please see additional Important Safety Information on the next page. Please see [Medication Guide](#).**



Please remove this card and fold along the dotted lines.

## Patient Wallet Card



Patient name: \_\_\_\_\_ EPKINLY start date: \_\_\_\_\_

Name of prescribing oncologist: \_\_\_\_\_ Office phone: \_\_\_\_\_

**Carry this card with you at all times. Show this card to any healthcare provider involved in your care.**

**Call or see your oncologist or get emergency help right away if you have any of these symptoms:**

#### Cytokine release syndrome (CRS)

- Fever of 100.4°F (38°C) or higher
- Dizziness or light-headedness
- Trouble breathing
- Chills
- Fast heartbeat
- Feeling anxious
- Headache
- Confusion
- Shaking (tremors)
- Problems with balance and movement, such as trouble walking

#### Immune effector cell–associated neurotoxicity syndrome (ICANS)

- Trouble speaking or writing
- Confusion and disorientation
- Drowsiness
- Tiredness or lack of energy
- Muscle weakness
- Shaking (tremors)
- Seizures
- Memory loss

**Please see additional Important Safety Information before separating card or visit [EPKINLY.com](#).**

### IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

This patient is receiving EPKINLY—which may cause serious side effects, including **cytokine release syndrome (CRS)** and **immune effector cell–associated neurotoxicity syndrome (ICANS)**.

- If CRS or ICANS is suspected, please refer to sections 2.6, 5.1, and 5.2 of the EPKINLY full Prescribing Information
- Please follow up with the prescribing oncologist about the management of this event

**For more information about EPKINLY, see full Prescribing Information at [EPKINLYhcp.com](#).**

### IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS (CONT'D)

To learn about adverse reaction management for EPKINLY, scan this QR code or visit [EPKINLYhcp.com](#).



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536. Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064. EPKINLY is a trademark of Genmab A/S ©2023 Genmab A/S and AbbVie. All rights reserved. 05/2023 COM-US-EPK-0000187



## IMPORTANT SAFETY INFORMATION (CONT'D)

**Due to the risk of CRS and neurologic problems,** you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY on day 15 of cycle 1. Your healthcare provider will monitor you for symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects, and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe.

**Do not** drive or use heavy or potentially dangerous machinery if you develop dizziness, confusion, tremors, drowsiness, or any other symptoms that impair consciousness until your symptoms go away. These may be symptoms of CRS or neurologic problems.

**EPKINLY can also cause other serious side effects, including:**

- **Infections.** EPKINLY can cause serious infections that may lead to death. Your healthcare provider will check you for symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts.** Low blood cell counts are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including **low white blood cell counts (neutropenia)**, which can increase your risk for infection; **low red blood cell counts (anemia)**, which can cause tiredness and shortness of breath; and **low platelet counts (thrombocytopenia)**, which can cause bruising or bleeding problems.

Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

**Before you receive EPKINLY, tell your healthcare provider about all of your medical conditions, including if you:**

- have an infection.
- are pregnant or plan to become pregnant. EPKINLY may harm your unborn baby. **Females who are able to become pregnant:** Your healthcare provider should do a pregnancy test before you start treatment with EPKINLY. You should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY.
- are breastfeeding or plan to breastfeed. It is not known if EPKINLY passes into your breast milk. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

**Tell your healthcare provider about all of the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements.

**The most common side effects of EPKINLY** include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea.

These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

**Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on previous page. Please see Medication Guide.**







# Treatment tracker

Record your experience with EPKINLY and share with your healthcare team so they get a full picture of how you're doing on treatment.

- Keep track of the appointment date for each dose
- Mark the location of the injection site
- Write down how you're feeling after the injection and any other information you want to share


ONCE A WEEK

## DOSE 1

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE A WEEK

## DOSE 2

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE A WEEK

## DOSE 3

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Treatment tracker


ONCE A WEEK

## DOSE 4

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE A WEEK

## DOSE 5

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE A WEEK

## DOSE 6

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE A WEEK

## DOSE 7

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_



# Treatment tracker


ONCE A WEEK

## DOSE 8

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_


ONCE A WEEK

## DOSE 9

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_


ONCE A WEEK

## DOSE 10

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Treatment tracker

ONCE A WEEK

## DOSE 11

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE A WEEK

## DOSE 12

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE EVERY 2 WEEKS

## DOSE 13

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE EVERY 2 WEEKS

## DOSE 14

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:





# Treatment tracker


ONCE EVERY 2 WEEKS

## DOSE 15

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE EVERY 2 WEEKS

## DOSE 16

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_


ONCE EVERY 2 WEEKS

## DOSE 17

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Treatment tracker


ONCE EVERY 2 WEEKS

## DOSE 18

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 2 WEEKS

## DOSE 19

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 2 WEEKS

## DOSE 20

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 2 WEEKS

## DOSE 21

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_





# Treatment tracker


ONCE EVERY 2 WEEKS

## DOSE 22

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 2 WEEKS

## DOSE 23

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

ONCE EVERY 2 WEEKS

## DOSE 24

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Treatment tracker


ONCE EVERY 4 WEEKS

## DOSE 25

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 4 WEEKS

## DOSE 26

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 4 WEEKS

## DOSE 27

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 4 WEEKS

## DOSE 28

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_



# Treatment tracker

ONCE EVERY 4 WEEKS

## DOSE 29

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

ONCE EVERY 4 WEEKS

## DOSE 30

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

ONCE EVERY 4 WEEKS

## DOSE 31

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Treatment tracker


ONCE EVERY 4 WEEKS

## DOSE 32

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 4 WEEKS

## DOSE 33

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_


ONCE EVERY 4 WEEKS

## DOSE 34

Date: \_\_\_\_\_

Time: \_\_\_\_\_

Injection Site:



How I'm feeling: \_\_\_\_\_

Questions/notes for my healthcare team: \_\_\_\_\_

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

Use this calendar to keep track of your healthcare appointments, including injections and tests. Make notes here prior to the appointment if you have questions for your healthcare provider.

**MONTH:** \_\_\_\_\_

SUN	MON	TUE	WED	THU	FRI	SAT
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).







# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).







# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).





# Calendar

**MONTH:**

SUN	MON	TUE	WED	THU	FRI	SAT

## Notes

---



---

Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7. Please see [Medication Guide](#).







Visit [EPKINLY.com](https://www.epkinly.com) for more information.

**Please see Important Safety Information, including Important Warnings on CRS and neurologic problems, on pages 6-7.**

**Please see [Medication Guide](#).**



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536.  
Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.  
EPKINLY and *MyNavCare* are trademarks of Genmab A/S. All other trademarks and registered trademarks are the property of their respective owners.  
©2023 Genmab A/S and AbbVie. All rights reserved. 05/2023 COM-US-EPK-0000037



**epkinly**<sup>™</sup>  
epcoritamab-bysp  
SUBCUTANEOUS INJECTION 4mg/48mg